t r a c t
Stimulant use may accelerate HIV disease progression through biological and behavioral pathways. However, scant research with treated HIV-positive persons has examined stimulant-associated alterations in pathophysiologic processes relevant to HIV pathogenesis. In a sample of 55 HIV-positive, methamphetamine-using sexual minority men with a viral load less than 200 copies/mL, we conducted RNA sequencing to examine patterns of leukocyte gene expression in participants who had a urine sample that was reactive for stimulants (n = 27) as compared to those who tested non-reactive (n = 28). Results indicated differential expression of 32 genes and perturbation of 168 pathways in recent stimulant users. We observed statistically significant differential expression of single genes previously associated with HIV latency, cell cycle regulation, and immune activation in recent stimulant users (false discovery rate p < 0.10). Pathway analyses indicated enrichment for genes associated with inflammation, innate immune activation, neuroendocrine hormone regulation, and neurotransmitter synthesis. Recent stimulant users displayed concurrent elevations in plasma levels of tumor necrosis factor -alpha (TNF-a) but not interleukin 6 (IL-6). Further research is needed to examine the bio-behavioral mechanisms whereby stimulant use may contribute to HIV persistence and disease progression.
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Introduction
Stimulant use may accelerate HIV disease progression via behavioral and biological mechanisms (Carrico, 2011; Salamanca et al., 2014) . HIV-positive stimulant users are more likely to have difficulties with HIV disease management that contribute to elevated HIV viral load and hastened disease progression (Carrico, 2011; Carrico et al., 2011; Ellis et al., 2003) . At the same time, recent findings from a cohort of HIV-positive sexual minority men receiving anti-retroviral therapy (ART) indicate that those who engaged in more frequent stimulant use had 50% greater odds of clinical progression even after accounting for adherence and viral load (Carrico et al., 2014) . Because most studies examining stimulant-associated immune dysregulation have relied on in vitro and animal models (Cabral, 2006) , research with treated HIV-positive persons is needed to elucidate the biological pathways whereby stimulants may promote disease progression.
Sympathetic nervous system activation could partially mediate the immunomodulatory effects of stimulants in HIV, but findings from preclinical and human studies are mixed. Methamphetamine activates the sympathetic nervous system (Irwin et al., 2007; Makisumi et al., 1998) leading to elevated norepinephrine, which has been linked to greater HIV replication (Cole et al., 1998; Ironson et al., 2015) . This is further supported by findings that sympathetic nervous activation and methamphetamine use may contribute to HIV persistence. For example, one prior study observed 3.9-fold greater rates of SIV replication at sites where lymph nodes juncture with catecholaminergic varicosities (Sloan et al., 2006) . Among HIV-positive persons who were virally suppressed, greater sympathetic nervous system activation (measured by a shorter cardiac pre-ejection period) has also been associated with greater intracellular HIV RNA but not higher proviral HIV
